Low Gradient Aortic Stenosis Won’t Improve with TAVR

Courtesy of Dr. Carlos Fava.

Low Gradient Aortic Stenosis Won’t Improve with TAVRIt is known that patients with low gradient aortic stenosis show poor evolution with medical treatment and, in addition, present high mortality rate with surgery. As regards TAVR, a far simpler procedure compared to surgery, there is contradicting evidence; while some studies claim it holds comparable risks, others have found benefits.

 

This study analyzed 8 studies including a total of 12,589 patients. Low gradient aortic stenosis was defined as aortic valve area (AVA) <1 cm2 with a mean gradient lower than 40 mmHg, except for Malkin, who defined it as AVA <1.

 

Primary end point was all cause mortality at 12 months, while the secondary was all cause mortality at 30 days.

 

All patients presented severe symptomatic aortic stenosis. 3,437 (27.3%) of them presented low gradient aortic stenosis.

 

Mean age was 81. Ejection fraction was lower in those presenting low gradient aortic stenosis (48% vs. 54%), higher presence of diabetes, coronary artery disease and EuroSCORE log.

 

Primary end point was higher in the low gradient AS group (OR; 1.48; 95% CI; 1.3-1.7; p<0.00001), as well as the secondary end point (OR, 1.35; 95% CI, 1.11-1.66; p=0.002). As regards age, ejection fraction, a history of heart disease and type of implanted valve, these factors did not impact mortality in the low gradient group.

 

Conclusion

In a population of patients undergoing TAVR, the presence of low gradient aortic stenosis seems to be associated to a dismal prognosis.

 

Comment

The presence of low flow and low gradient is a challenge in this disease, since it is associated with higher early mortality after surgery, and this analyzis shows the same.

We should learn to be wary not only of AS diagnosis (acknowledging symptoms, assessing ventricular function and ejection fraction), but also of systolic volume index, associated to early ventricular function deterioration.

 

Courtesy of Dr. Carlos Fava.

 

Original Title: Outcomes of Patients with Low-Pressure Aortic Gradient Undergoing Transcatheter Aortic Valve Implantation: a Meta-analysis.

Reference: Federico Carnotto, et al. Catheterization and Cardiovascular Intervention 2017;89:1100-1106.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...